Real-World Study Finds Treatment Effective for Pediatric, Adolescent Atopic Dermatitis

In real-world practice, dupilumab was effective and well-tolerated for the treatment of pediatric and adolescent atopic dermatitis, according to study results published in The Journal of Allergy and Clinical Immunology: In Practice.

Researchers from the Icahn School of Medicine at Mount Sinai Department of Dermatology, New York, NY, reviewed electronic medical records at a single center and identified 89 patients with moderate to severe atopic dermatitis who started dupilumab when they were younger than 18 years. Among them, the treatment duration averaged 1.3±.9 years.

Assessments for 73 patients at baseline and weeks 12 to 24 revealed average improvements of 63.1% ± 29.2% in body surface area (BSA) score, 39.6% ± 29.9% in Eczema Area and Severity Index (EASI) score, and 59.6% ± 30.7% in Investigator Global Assessment (IGA) score, according to study authors.

Findings showed among 23 patients treated with dupilumab for 12 months or longer, all achieved EASI-75 and IGA 0/1. Nearly two-thirds (60.8%) achieved EASI-90.

A history of atopy was linked with greater BSA improvement by weeks 12 through 24, reported researchers.

“Twelve patients (13.5%) had adverse events, of which conjunctivitis (5.6%) and joint pain (2.2%) were most common,” they added. “There were no serious adverse events.”

Reference:
Pagan AD, David E, Ungar B, Ghalili S, He H, Guttman-Yassky E. Dupilumab improves clinical scores in children and adolescents with moderate-to-severe atopic dermatitis: a real-world, single-center study. J Allergy Clin Immunol Pract. June 23, 2022. doi:10.1016/j.jaip.2022.06.014